Nivalis Therapeutics Inc. plans to lay off 80% of its workforce, including President and Chief Executive Jon Congleton, as part of its restructuring plan. That will leave the company with 5 employees out of its current total 30. The reduction in staff is aimed at preserving the company’s cash as it explores various options. The clinical-stage pharmaceutical company said it expects to book restructuring-related costs of $3 million but will have $45 million to $47 million to pursue strategic deals. Meanwhile, Nivalis named Chief Financial Officer Michael Carruthers as interim president, effective Jan. 15. Shares rose 2.3% after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News